Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer

RE Langley, IF Godsland, H Kynaston, NW Clarke, SD Rosen, RC Morgan, P Pollock, R Kockelbergh, El-Nasir Lalani, D Dearnaley, M Parmar, PD Abel

    Research output: Contribution to journalArticle

    34 Citations (Scopus)

    Abstract

    OBJECTIVE To assess the hormonal effects of Fem7 (R) (Merck, KGaA, Darmstadt, Germany) 100 mu g transdermal oestrogen patches on men undergoing first-line androgen-deprivation therapy for prostate cancer. PATIENTS AND METHODS PATCH is a multicentre, randomized, phase II trial for men with locally advanced or metastatic prostate cancer, comparing luteinizing hormone-releasing hormone agonist therapy with oestrogen patches. To assess the dosing schedule for the patches. as this was the first time that this brand of patch had been used in men, and to reassure patients and participating clinicians, the Independent Data Monitoring Committee agreed to early release of hormonal data from this study. RESULTS Oestradiol, testosterone and prostate-specific antigen (PSA) levels are presented for the first group of 14 patients who received the patches (with I withdrawal) and for whom there were >= 12 weeks of follow-up by March 2007. After 12 weeks, testosterone levels (nmol/L) in eight of the 13 patients were 1.7, two were 1.7-2 and three were >2. The median (range) serum oestradiol levels was 442 (52.1-1542) pmol/L and all patients had a PSA response, with eight having a PSA level of
    Original languageEnglish
    Pages (from-to)442-445
    Number of pages4
    JournalBJU international
    Volume102
    Issue number4
    DOIs
    Publication statusPublished - 1 Aug 2008

    Keywords

    • hormone therapy
    • randomized controlled trial
    • prostate cancer
    • transdermal oestrogen patches

    Fingerprint

    Dive into the research topics of 'Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer'. Together they form a unique fingerprint.

    Cite this